Disclaimer
These are general guidelines only and may not apply in the case of any particular individual patient. They should be applied bearing in mind the local situation. The health care worker should always use his/her clinical judgement and expertise.

Duality of Interest
No duality of interest was identified.
# Contents

List of Tables .......................................... v

Figure .................................................. v

List of Appendices ........................................ vi

Preface .................................................. vii

Acknowledgements ......................................... viii

Introduction ............................................. 1

Aim and Objectives ....................................... 3

Overview of Diabetes Mellitus .......................... 4

**SECTION I: SCREENING AND THE DIAGNOSIS OF DIABETES MELLITUS** ............................................. 5

- Risk Factors for Diabetes Mellitus .................. 7
- Screening for Type 2 Diabetes Mellitus .............. 7
- The Screening Test ..................................... 8
- Diagnostic Criteria and Classification of Diabetes Mellitus ............................................. 9
- Diagnostic Criteria of Impaired Fasting Glucose and Impaired Glucose Tolerance .................. 10
- The Metabolic Syndrome ............................. 10

**SECTION II: EFFECTIVE DELIVERY OF CARE** ............................................. 12

- Requirements for the Effective Delivery of Care ............................................. 13
- Patient Visits ......................................... 15
  - The Initial Visit .................................... 15
  - Follow-up Visits .................................... 17

**SECTION III: CONTROL OF BLOOD GLUCOSE, BLOOD PRESSURE AND BLOOD LIPIDS** ............................................. 19

Achieving Glycaemic Control ............................ 21
- Non-pharmacological Management of Hyperglycaemia ............................................. 21
  - Nutritional management ................................ 21
  - Physical activity .................................... 24
# Table of Contents

- Pharmacological Management of Hyperglycaemia .......................... 26  
  - Oral Glucose Lowering Agents .................................................. 26  
  - Insulin ....................................................................................... 29  
Monitoring of Blood Glucose ............................................................. 32  
Hypoglycaemia .................................................................................. 34  
Conditions in Diabetes Mellitus Requiring Hospital Admission .......... 36  
Management of Associated Conditions .......................................... 37  
  - Hypertension Management in Adults with Diabetes .................... 37  
  - Lipid Management in Adults with Diabetes ................................. 39  
  - Other Therapeutic Interventions .................................................. 40  

SECTION IV: PREVENTION AND REDUCTION OF COMPLICATIONS .......... 42  
  - Nephropathy .............................................................................. 43  
  - Retinopathy ................................................................................ 45  
  - Neuropathy ................................................................................ 45  
  - Care of the Foot ......................................................................... 46  
  - Cardiovascular Disease .............................................................. 46  

SECTION V: MANAGEMENT OF GESTATIONAL DIABETES ......................... 48  
  - Gestational Diabetes Mellitus ...................................................... 49  
  - Protocol for Testing for Gestational Diabetes Mellitus ............... 50  
  - Post-partum Follow-up ............................................................... 52  

SECTION VI: EFFECTIVE SELF CARE THROUGH EDUCATION ................ 53  
  - Self-Management Educational Goals .......................................... 54  

References & Abbreviations ................................................................. 58  
References ......................................................................................... 59  
Abbreviations .................................................................................... 62  
Appendices .......................................................................................... 63  
Members of Guidelines Committee ..................................................... 71
List of Tables

Table 1:  Presentation of Types 1 and 2 Diabetes Mellitus  ........................................... 5
Table 2:  Criteria for the Diagnosis of Diabetes Mellitus ................................................. 9
Table 3:  Criteria for the Diagnosis of Impaired Fasting Glucose
        and Impaired Glucose Tolerance ............................................................................. 10
Table 4:  Criteria for Identification of the Metabolic Syndrome .................................... 11
Table 5:  Metabolic, Blood Pressure and Nutritional Targets
        for Control in Diabetes Mellitus and Associated Conditions .......................... 20
Table 6:  Guide to Physical Activity Level ....................................................................... 25
Table 7:  Profile of Principal Oral Glucose-Lowering Agents ........................................ 28
Table 8:  Types of Insulin Available ............................................................................... 29
Table 9:  Definition of Abnormalities in Renal Albumin Excretion ................................. 44
Table 10: Glucose Tolerance Tests for Gestational Diabetes ........................................ 51

Figure

Therapeutic Management of Type 2 Diabetes Mellitus .................................................. 23
List of Appendices

<table>
<thead>
<tr>
<th>Appendix</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appendix I</td>
<td>Body Mass Index (BMI) Chart for Identifying Target Weight</td>
<td>64</td>
</tr>
<tr>
<td>Appendix II</td>
<td>Recommended Composition of Health Diets</td>
<td>77</td>
</tr>
<tr>
<td>Appendix III</td>
<td>Diabetes Management Flow Sheet</td>
<td>67</td>
</tr>
<tr>
<td>Appendix IV</td>
<td>Sick Day Rules</td>
<td>69</td>
</tr>
<tr>
<td>Appendix V</td>
<td>Care of the Foot in Persons with Diabetes</td>
<td>70</td>
</tr>
</tbody>
</table>
PREFACE

The Caribbean Health Research Council (CHRC) has a mandate to promote health policy decisions and best practice, based on available evidence. Consistent with this remit, the Council produced two manuals: “Managing Diabetes in Primary Care” and “Managing Hypertension in Primary Care in the Caribbean” in 1995 and 1998, respectively. These clinical guidelines were distributed throughout the Primary Health Care system of the entire English speaking Caribbean, targeting all Primary Care doctors, nurses, nurse practitioners and other health care personnel involved in the care of persons with diabetes and hypertension.

Since then, there have been significant advances in the management of these two conditions. Consequently, there is a need for updated manuals that would take into account the most recent international guidelines and regional expert opinions on the management of high blood pressure, diabetes, obesity and related dyslipidemia.

These manuals are geared to the culture, economic situation and health care systems in the Caribbean and are designed to serve as key tools in improving patient care. Special situations and local conditions (cultural and economic) may call for modified strategies, but the most important goal is to ensure that these diseases are managed effectively, thus reducing morbidity and mortality.

It is hoped that the collaboration between the CHRC, the Pan American Health Organization (PAHO), regional opinion leaders and other agencies will accelerate a more effective and comprehensive approach to the prevention and control of chronic non communicable diseases.

Caribbean Health Research Council
St. Augustine
Trinidad and Tobago

Office of Caribbean Programme Coordination
Pan American Health Organization
Barbados

April, 2006
ACKNOWLEDGEMENTS

The Caribbean Health Research Council and the Office of Caribbean Program Coordination, Pan American Health Organization/World Health Organization acknowledge with appreciation the contribution of several persons to the successful completion of this manual.

- Drs Anselm Hennis, Glenda Maynard, Carlisle Goddard, Dan Ramdath and Donald Simeon who were responsible for the compilation and the editing of the various versions of the document.

- The technical persons who assisted in providing technical input and invaluable comments:
  - Members of the Guidelines Committee
  - Chief Medical Officers of the English-speaking Caribbean countries
  - Dr Sylvia Robles and Dr Alberto Barcelo from PAHO, Washington; Dr Gerardo de Cosio, PAHO, Jamaica
  - The late Dr Deepak Mahabir, Ministry of Health, Trinidad and Tobago
  - Staff of the Tropical Medicine Research Institute, The University of the West Indies (UWI), Mona, Jamaica
  - Staff of the School of Clinical Medicine and Research, University of the West Indies (UWI), Barbados
  - Dr Sonia Roache, Caribbean College of Family Practitioners

- Dr Paul Teelucksingh, Faculty Medical Sciences, UWI, Trinidad and Tobago

- The multidisciplinary technical teams from Barbados and Grenada who ensured that the document would be suitable for use in Primary Care
Dr Pauline Samuda and Mr Godfrey Xuereb from the Caribbean Food and Nutrition Institute

Ms Simone Lorde who provided information on the care of the feet
INTRODUCTION

The World Health Organization (WHO) estimated the worldwide prevalence of diabetes in adults to be around 173 million in 2002 and predicted that there will be at least 350 million people with Type 2 diabetes by 2030. At present about two-thirds of persons with diabetes live in developing countries and the majority of new cases will originate from these areas. The global increase in the incidence of diabetes is related to high levels of obesity associated with a change from traditional diets, diminishing levels of physical activity, population ageing and increasing urbanization.

Diabetes prevalence has been increasing in most countries of the Region of the Americas. It is estimated that more than 1 in 10 of the adult population of the Region is affected; rising to 1 in 5 in persons over 40 years of age. With current trends and without effective interventions, this prevalence is expected to rise.

Diabetes mellitus is one of the leading health problems in the Caribbean, contributing significantly to morbidity and mortality and adversely affecting both the quality and length of life.

In the Caribbean, higher prevalence in women correlates with higher levels of obesity. There is evidence to suggest that the prevalence of Type 2 diabetes is increasing in children and adolescents, which is also likely to be due to an increasing prevalence of obesity in these groups. Consistent with other reports, a study conducted in Trinidad and Tobago showed that persons of South Asian origin had a higher prevalence of diabetes than other ethnic groups, highlighting the relevance of ethnicity as a risk factor.

Diabetes more often affects people of lower socio-economic status who carry a greater disease burden for many reasons including limited access to or utilization of health care, poor nutrition, and sub-optimal physical activity. The disease also places a heavy economic burden on already limited health care resources in the Caribbean. Costs are related directly to treatment of the disease and its complications, and indirectly to loss of earning power in those affected.
Introduction

Globally, diabetes represents the 3rd and 10th tenth leading cause of loss of years of potential life among women and men, respectively. In 2000, diabetes mellitus was the 3rd leading cause of mortality in the Caribbean region, accounting for approximately 10% of all deaths. Those aged 45-64 years were particularly affected.

The United Kingdom Prospective Diabetes Study (UKPDS) confirmed that approximately 50% of persons with Type 2 diabetes have evidence of both vascular complications and significant deficiency in pancreatic beta cell function at the time of diagnosis. Earlier diagnosis coupled with effective and aggressive treatment may lead to improved outcomes.

In Caribbean populations, diabetes often co-exists with obesity, hypertension and dyslipidaemia. The presence of any one of these conditions should therefore alert the health care provider to the increased likelihood of the existence of the others.

Studies suggest that lifestyle modification at the stage of impaired fasting glycaemia or impaired glucose tolerance (i.e. pre-diabetes) may reduce the risk of developing diabetes by as much as 60%. Achieving diabetes control is also eminently possible through lifestyle change and therapeutic interventions.

This document provides a pragmatic approach to the diagnosis as well as the management of diabetes mellitus at the Primary Care level. The focus is on Type 2 diabetes which affects over 95% of persons with diabetes in the Caribbean. The importance of non-drug or lifestyle management and the need to educate patients, families, communities and health care workers are stressed.

This manual aims to provide management guidelines based on current knowledge and best practice. It is hoped that these guidelines will be systematically applied and thus lead to improved care and outcomes in persons with diabetes in the Caribbean.
AIMS & OBJECTIVES:

AIM:

To produce a unified, evidence-based approach to the management of diabetes in the Caribbean

OBJECTIVES:

• To prevent or delay the onset of diabetes mellitus and co-morbid conditions of obesity, hypertension and dyslipidaemia

• To promote earlier diagnosis of diabetes mellitus

• To improve the quality of care of persons with diabetes mellitus

• To prevent and treat acute and long-term complications of diabetes mellitus

• To promote education and empowerment of the patient, family and community, and health care worker
OVERVIEW OF DIABETES MELLITUS

Diabetes mellitus is defined by the World Health Organization as a metabolic disorder characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.

The symptoms of marked hyperglycaemia include:

- Polyuria
- Polydipsia
- Weight loss which may sometimes be associated with polyphagia.
- Blurred vision

There are several types of diabetes mellitus which may be classified as follows:

1. **Type 1 Diabetes Mellitus**
   Type 1 diabetes occurs in young people. The onset of illness is usually abrupt and associated with ketoacidosis. These patients require insulin and must be referred urgently to a diabetes specialist or emergency department when acutely ill.

2. **Type 2 Diabetes Mellitus**
   Type 2 diabetes occurs mainly in older persons and is associated with overweight and lack of physical activity. There is also a marked family history in persons with this disease. Type 2 diabetes is associated with the metabolic syndrome.

3. **Gestational Diabetes**
   Gestational diabetes refers to glucose intolerance developing during pregnancy. Persons with this condition must be referred for specialist care. This condition is a recognized risk factor for the subsequent development of diabetes mellitus. See Page 56
4. **Other types of Diabetes Mellitus**

Specific genetic defects or diseases of the exocrine pancreas such as complications of pancreatitis, endocrinopathies, or exposure to specific drugs or chemicals can lead to other types of diabetes mellitus.

Types 1 and 2 are the main types of diabetes and a summary of their usual presentation is found in Table 1.

**Table 1:**
Presentation of Types 1 and 2 Diabetes Mellitus

<table>
<thead>
<tr>
<th>Features</th>
<th>Type 1 (Formerly insulin-dependent diabetes- IDDM)</th>
<th>Type 2 (Formerly non-insulin-dependent diabetes- NIDDM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Occurrence</td>
<td>Accounts for about 5% of cases</td>
<td>Accounts for about 95% of cases</td>
</tr>
<tr>
<td>Pathogenesis</td>
<td>Auto-immune pancreatic beta cell destruction</td>
<td>Relative insulin deficiency and insulin resistance</td>
</tr>
<tr>
<td>Age of onset</td>
<td>Usually before age 30 years</td>
<td>45 years and above [but diagnosis at an earlier age appears to be increasing]</td>
</tr>
<tr>
<td>Onset</td>
<td>Abrupt</td>
<td>Gradual</td>
</tr>
<tr>
<td>Insulin requirement</td>
<td>Insulin therapy required for survival</td>
<td>May initially be managed by lifestyle changes and oral glucose-lowering agents, but eventually may require insulin for control</td>
</tr>
<tr>
<td>Ketosis</td>
<td>Ketosis prone</td>
<td>Ketosis resistant except with severe stress</td>
</tr>
<tr>
<td>Family history</td>
<td>Minor</td>
<td>Marked</td>
</tr>
</tbody>
</table>
Section I:

Screening and the Diagnosis of Diabetes Mellitus
RISK FACTORS FOR TYPE 2 DIABETES MELLITUS

- Overweight (Body Mass Index $\geq 25$ kg/m$^2$)
- Age 45 years and older
- Physical inactivity
- Diabetes in a first-degree relative
- Prior gestational diabetes or history of delivering a baby $>4$ kg (9 lb)
- Polycystic ovary syndrome
- History of Impaired Glucose Tolerance (IGT) or Impaired Fasting Glucose (IFG)
- HDL-C level $\leq 35$ mg/dL [$\leq 0.90$ mmol/L] and/or Triglyceride level $\geq 250$ mg/dL [$\geq 2.82$ mmol/L]
- Race/ethnicity (e.g. persons of Asian and African descent)
- Presence of coronary artery disease and/or hypertension (blood pressure $\geq 140/90$ mm Hg)
- Presence of other vascular complications

SCREENING FOR TYPE 2 DIABETES MELLITUS

Screening involves the testing of individuals who are at risk of having the disease. Population-based screening is expensive and therefore priority should be given to persons with identifiable risk factors. However, where possible and affordable, population-based screening should be encouraged.
Reasons for screening include:

- There is a rising prevalence in the Caribbean.
- Diabetes is an important public health problem as Caribbean populations are, by definition, high-risk.
- There is a long, latent asymptomatic period in which the condition can be detected.
- At the time of diagnosis, significant numbers of individuals already have evidence of the micro-vascular complications of diabetes and may also have macrovascular disease.
- There is evidence that early treatment improves long-term outcome.

**THE SCREENING TEST**

The fasting plasma glucose (FPG) is the recommended screening test. The 75 gm Oral Glucose Tolerance Test (OGTT) is more sensitive for detecting glucose intolerance but is not recommended for screening as it is more expensive and less practical.

Testing of glucose in the urine is **not** recommended for screening. Blood glucose testing by glucometers may play a role in initial screening but **cannot** be used for diagnosis. Any abnormal results **must** be confirmed by measurement of plasma glucose.

If the test result is normal but the client is 45 years or older (particularly if overweight) re-screening would be appropriate at 3-yearly intervals. If the person is overweight and has additional risk factors such as a positive family history or co-morbid disorders, re-screening should be done more frequently.
DIAGNOSTIC CRITERIA AND CLASSIFICATION OF DIABETES MELLITUS

The diagnosis of diabetes mellitus must be based on laboratory venous blood test results.

Glycosuria and finger-prick glucose measurements using a glucometer should not be used for the diagnosis of diabetes.

The HbA1c test is not recommended for diagnostic purposes.

We recommend that the diagnosis of diabetes mellitus be made using the criteria of the American Diabetes Association (ADA).

Table 2:
Criteria for the Diagnosis of Diabetes Mellitus

1. Symptoms of diabetes plus casual plasma glucose concentration ≥200 mg/dL (≥11.1 mmol/L). Casual is defined as any time of day without regard to time since last meal.
   Or

2. FPG ≥126 mg/dL (≥7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h.
   Or

3. 2-h post-load glucose ≥200 mg/dL (≥11.1 mmol/L) during an OGTT. The test should be performed as described by the WHO, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.

In the absence of unequivocal hyperglycemia, these criteria should be confirmed by repeat testing on a different day. The third measure (OGTT) is not recommended for routine clinical use.
DIAGNOSTIC CRITERIA FOR IMPAIRED FASTING GLUCOSE AND IMPAIRED GLUCOSE TOLERANCE

If the FPG ranges from 100–125 mg/dL (5.6-6.9 mmol/L) or the blood sugar 2 hours after a 75 gm glucose load is between 140-199 mg/dL (7.8-11.1 mmol/L), an individual is considered to have impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) respectively, and is classified as ‘pre-diabetes’.

Such persons are at high risk of developing diabetes and cardiovascular disease. Indeed impaired fasting glucose and impaired glucose tolerance frequently co-exist with other cardiovascular risk factors giving rise to the Metabolic Syndrome.

**Table 3:**
Criteria for the Diagnosis of Impaired Fasting Glucose and Impaired Glucose Tolerance

<table>
<thead>
<tr>
<th></th>
<th>Fasting Plasma Glucose</th>
<th>2h Plasma Glucose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>≤100 mg/dL (&lt;5.6 mmol/L)</td>
<td>and &lt;140 mg/dL (&lt;7.8 mmol/L)</td>
</tr>
<tr>
<td>Impaired Fasting Glucose (IFG)</td>
<td>100–125 mg/dL (5.6-6.9 mmol/L)</td>
<td></td>
</tr>
<tr>
<td>Impaired Glucose Tolerance (IGT)</td>
<td></td>
<td>140–199 mg/dL (7.8-11.1 mmol/L)</td>
</tr>
</tbody>
</table>

Source: Adapted from the American Diabetes Association 2005

**The Metabolic Syndrome**

The metabolic syndrome is characterized by the co-occurrence of obesity (especially central obesity), dyslipidaemia (especially high levels of triglycerides and low levels of high density lipoprotein cholesterol), hyperglycaemia and hypertension. The diagnosis of metabolic syndrome is made if an individual has three or more of the characteristics shown in Table 4.

There is a large overlap between the Metabolic Syndrome and pre-diabetes. Persons with the metabolic syndrome are at increased risk of developing diabetes.
### Table 4:
Criteria for Identification of the Metabolic Syndrome

<table>
<thead>
<tr>
<th>Feature</th>
<th>Criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Abdominal obesity (waist circumference)</td>
<td></td>
</tr>
<tr>
<td>- Men</td>
<td>&gt; 102 cm (40 in)</td>
</tr>
<tr>
<td>- Women</td>
<td>&gt; 88 cm (35 in)</td>
</tr>
<tr>
<td>2 Fasting Plasma Lipids</td>
<td></td>
</tr>
<tr>
<td>- Triglycerides</td>
<td>≥ 150 mg/dL (≥ 1.69 mmol/L)</td>
</tr>
<tr>
<td>- HDL Cholesterol</td>
<td></td>
</tr>
<tr>
<td>- Men</td>
<td>&lt; 40 mg/dL (&lt; 1.03 mmol/L)</td>
</tr>
<tr>
<td>- Women</td>
<td>&lt; 50 mg/dL (&lt; 1.29 mmol/L)</td>
</tr>
<tr>
<td>3 Blood Pressure</td>
<td>≥ 130/85 mm Hg</td>
</tr>
<tr>
<td>4 Fasting Blood Glucose</td>
<td>≥ 110 mg/dL (≥ 6.1 mmol/L)</td>
</tr>
</tbody>
</table>

Source: Executive summary of the third report of the 2001 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel (ATP)) III
Section II: Effective Delivery of Care
Requirements for the Effective Delivery of Care

Some of the requirements for the effective delivery of care are adequate personnel, facilities, equipment and supplies. Good information and referral systems are also essential elements.

Personnel

The management of diabetes depends on the functioning of a multidisciplinary team. The composition of the team will depend on the country’s resources but should include:

- Medical Doctor/Medex¹/Nurse Practitioner
- Nurse
- Diabetes Educator
- Nutritionist/Dietitian
- Podiatrist/Chiropodist
- Pharmacist
- Social Worker

There should be access to other health professionals such as an endocrinologist or diabetes specialist, physiotherapist, psychologist, ophthalmologist and nephrologist.

The staff should be trained to ensure that the services are patient-centred and to accept the patient as an important member of the team who should be fully involved in his/her care.

¹Category of health care worker in Guyana - similar to a Physician Assistant
Facilities

The facilities should be easily accessible to persons with disabilities. Adequate space should be provided for:

- Registration of the patient
- Education and counselling
- Physical examination

There should be access to laboratory services.

Equipment and Supplies

Equipment related to the management of diabetes should be available. These include:

- Glucose monitors
- Testing materials such as glucometers strips, lancets, etc
- Beam balance scale and stadiometer
- Measuring tape (non-stretch), tuning fork, ophthalmoscope, 10G monofilament
- Audiovisual equipment and printed material for patient and staff education

Information System

The information system plays an important role. The system should include:

- records for collection of client information
- mechanism for client recall- annual reviews etc....
- system for assessing quality of care
Patient Visits

The person with diabetes should have regular contact with the health system. The following is a suggested schedule of visits and activities.

The Initial Visit

Medical History

A comprehensive medical history should be elicited to determine the client’s baseline information. This includes:

- Symptoms
- History of other medical conditions
- Medications being used
- Risk factor assessment
  - Smoking
  - Alcohol intake
  - Exercise patterns
  - Nutrition
  - Family history of diabetes, hypertension, vascular disease
  - Psychosocial assessment

- Identify factors that may affect management of diabetes
  - Cultural
  - Educational
  - Socio-economic

If patient is already being treated:

- Obtain results of previous test results
- Obtain information about previous treatments

Physical Examination

A thorough physical examination should be done paying special attention to:

- Height and weight to determine BMI (See Appendix I)
• Waist circumference
  See “Protocol for the Nutritional Management of Obesity, Diabetes and Hypertension in the Caribbean”, produced by the CFNI, for further details.

• Blood pressure (including checks for orthostatic hypotension)

• Skin for evidence of infections, ischaemia, ulcers and state of insulin injection sites

• Eyes for evidence of diabetic retinopathy [such as microaneurysms, haemorrhages and exudates], visual acuity

• Mouth for gingivitis, periodontitis

• Heart for cardiomegaly and murmurs

• Abdomen for hepatomegaly

• Feet for evidence of peripheral artery disease and neuropathy
  o Appearance- colour, evidence of atrophy, nails, ulcers
  o Sensation, reflexes, vibration
  o Pulses- dorsalis pedis, posterior tibial

• Neurological system for evidence of cranial and peripheral neuropathy

**Laboratory Tests**

The following laboratory tests should be conducted:

• Blood
  o Haemoglobin
  o Fasting Plasma glucose
  o HbA1c
  o Fasting lipid profile- low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), Triglycerides (TG)
  o Serum creatinine

If clinically indicated
  o Thyroid function tests
  o Liver function tests
Referrals
Where available the client should be referred to the following personnel:

- Nutritionist/Dietitian
- Diabetes Educator
- Ophthalmologist
- Chiropodist/Podiatrist
- Medical Social Worker
- Other specialists as indicated

FOLLOW-UP VISITS
Please see Appendix II for the Diabetes Management Flow Sheet.

EVERY VISIT

All patients:

- Measure weight
- Determine BMI (using initial height)
- Measure blood pressure
- Review self-monitoring of blood glucose results and reinforce its importance
- Elicit information on adherence to treatment
- Ask about symptoms including those of hypoglycaemia
- Conduct visual inspection of feet
- Give advice on nutrition and physical activity.
Insulin treated patients

- Inspect injection sites
- Ask about occurrence of hypoglycaemic attacks
- Test urine for ketones, if ill

EVERY 3-6 MONTHS

- Measure HbA1c

ANNUAL REVIEW FOR ALL PATIENTS

General

- Measure weight
- Determine BMI
- Measure waist circumference
- Measure blood pressure
- Ask about frequency of smoking and alcohol use
- Review diet - especially if overweight or plasma glucose and/or HbA1c are unacceptable
- Ask about mental health (especially depression)

Physical Examination

Pay special attention to:

- Feet
- Eyes
- Mouth

Laboratory Investigations

Blood

- HbA1c
- Lipids
- Creatinine

Urine

- Microalbuminuria  (See Page 49)

Other Test

- Electrocardiogram for persons over 40
Section III:

Control of Blood Glucose, Blood Pressure and Blood Lipids
### Table 5:
**Metabolic, Blood Pressure and Nutritional Targets**
for Control in Diabetes Mellitus and Associated Conditions

<table>
<thead>
<tr>
<th>Measurement</th>
<th>Good</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood glucose:</strong></td>
<td></td>
</tr>
<tr>
<td>- Preprandial</td>
<td>90-130 mg/dL (5.0-7.2 mmol/L)</td>
</tr>
<tr>
<td>- Postprandial</td>
<td>&lt;180 mg/dL (&lt;10.0 mmol/L)</td>
</tr>
<tr>
<td><strong>HbA1c</strong></td>
<td>&lt;6.5%</td>
</tr>
<tr>
<td><strong>Total cholesterol</strong></td>
<td>&lt;200 mg/dL (&lt;5.2 mmol/L)</td>
</tr>
<tr>
<td><strong>HDL cholesterol</strong></td>
<td>&gt;40 mg/dL (&gt;1.0 mmol/L)</td>
</tr>
<tr>
<td><strong>LDL cholesterol</strong></td>
<td>&lt;70 mg/dL (&lt;1.8 mmol/L)</td>
</tr>
<tr>
<td><strong>Fasting triglycerides</strong></td>
<td>&lt;150 mg/dL (&lt;1.7 mmol/L)</td>
</tr>
<tr>
<td><strong>Blood Pressure</strong></td>
<td>≤130/80 mmHg</td>
</tr>
<tr>
<td><strong>Body Mass Index</strong></td>
<td>18.5 - 25 kg/m²</td>
</tr>
<tr>
<td><strong>Waist circumference:</strong></td>
<td></td>
</tr>
<tr>
<td>Women</td>
<td>&lt;80 cm (&lt;32&quot;)</td>
</tr>
<tr>
<td>Men</td>
<td>&lt;94 cm (&lt;37&quot;)</td>
</tr>
</tbody>
</table>
ACHIEVING GLYCAEMIC CONTROL

NON PHARMACOLOGICAL MANAGEMENT OF HYPERGLYCAEMIA

Weight management, diet and physical exercise should be the first line of treatment for diabetes mellitus and should be maintained throughout the course of the disease. In addition to improving glycaemic control, these interventions also slow progression of impaired glucose tolerance to overt diabetes.

NUTRITIONAL MANAGEMENT

Assess
Nutritional status using BMI (See Appendix 1) or waist circumference

• Body mass index (BMI) has been the traditional index of obesity and usefully identifies the risk of diabetes and cardiovascular disease in a given population.

• Waist Circumference
The waist circumference is a marker of visceral adiposity and a strong predictor of diabetes and cardiovascular disease risk.

Elicit
Information on dietary practices

Advice on Nutrition
• Overweight patients should reduce calorie intake i.e. eat smaller portions and increase physical activity.
• Limit intake of fats and oils; avoid fried foods.

“Lifestyle measures, principally changes in nutritional habits and physical activity, may reverse some of the glucose, lipid and blood pressure disorders of diabetes.”

Diabetes Voice
May 2003
• The intake of saturated fat, margarine and hydrogenated oils should be reduced.
• Consumption of red meat should be limited and increased intake of fish, white meat and legumes encouraged.
• Increased intake of complex carbohydrates and high fibre foods should be encouraged.
• The intake of refined carbohydrates (sugars) should be reduced.
• The intake of salt and high sodium foods should be reduced.
• Eat a variety of foods and include fresh fruits and vegetables.
• Meals should be evenly distributed throughout the day. Breakfast, lunch and dinner should be taken at fairly regular times with mid morning, mid afternoon and bedtime snacks. This is especially important for patients treated with insulin.

See also Appendix II for the recommended composition of health diets.

Refer

To nutritionist/dietitian where available, especially for new patients or if dietary indiscretion is recognized

See “Protocol for the Nutritional Management of Obesity, Diabetes and Hypertension in the Caribbean” as well as Appendix II for the recommended composition of health diets.
**Figure. Therapeutic Management of Type 2 Diabetes Mellitus**

(Modified from Diabetic Medicine 1988;5:275-81)

- **Overweight BMI 25.0 - 29.0 kg/m²**
  - Weight Reducing DIET & EXERCISE
    - GOOD CONTROL
    - POOR CONTROL
    - Reinforce DIET (Low Fat) & EXERCISE
      - GOOD CONTROL
      - POOR CONTROL
      - Add METFORMIN reinforces DIET & EXERCISE
        - GOOD CONTROL
        - POOR CONTROL
        - Trial of combination therapy
          - GOOD CONTROL
          - POOR CONTROL
          - INSULIN (singly or in combination with oral glucose lowering therapy), continue DIET & EXERCISE

- **Obese BMI ≥30 kg/m²**

- **Non-obese BMI <25.0 kg/m²**

- **Severe Symptoms ± Infection**
  - POOR CONTROL
  - Reinforce DIET & EXERCISE
    - POOR CONTROL
    - GOOD CONTROL

- **Add Sulphonylurea or other drugs**
  - Reinforce DIET & EXERCISE
    - POOR CONTROL
    - GOOD CONTROL

- **Trial of combination therapy**
  - POOR CONTROL
  - GOOD CONTROL
PHYSICAL ACTIVITY

Physical inactivity and overnutrition leading to obesity, are major contributors to the increasing levels of Type 2 Diabetes worldwide. Physical activity is therefore a key factor both in the prevention and management of Type 2 diabetes.

Assess
Physical activity levels

Advise clients about the benefits of regular physical activity which include:

- Improvement in glycaemic control
- Prevention of cardiovascular disease
- Reduction in hypertension
- Reduction in levels of VLDL and increase in HDL cholesterol levels
- Enhancement of weight loss or maintenance of weight
- Improvement in mental health (helps counter anxiety and depression)

Meeting the requirements for physical activity does not require a formal exercise regime. Physical activity can be incorporated into the activities of daily living. See Table 6.

Regular aerobic activity should be sustained for 30-60 minutes at least 5 times weekly. The level and intensity of physical activity should be guided by the age and ability of the patient.
Table 6:
Guide to Physical Activity Levels

<table>
<thead>
<tr>
<th>Level of Activity</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Light</td>
<td>Office work, cleaning house, playing golf, walking</td>
</tr>
<tr>
<td>Moderate</td>
<td>Walking briskly, gardening, cycling, tennis, dancing, swimming, light weight training, climbing stairs</td>
</tr>
<tr>
<td>Strenuous</td>
<td>Jogging, competitive swimming and tennis, aerobic workout, vigorous dancing</td>
</tr>
<tr>
<td>Very Strenuous</td>
<td>Running, intense aerobic workout, intense weight training, football</td>
</tr>
</tbody>
</table>

Note: These are simply a few examples. Physical activity levels will be determined by the degree of exertion. Before commencing a physical activity program, persons with diabetes should be assessed by a medical doctor.

Elicit medical history including:
- Present status of disease including, symptoms, treatment, complications
- Cardiac history
- Family history

Conduct physical examination including:
- Measurement of BMI, waist circumference
- Cardiac assessment
- Identification of complications of diabetes
- Foot examination

The history and physical examination should reveal any precautions that must be taken.

Contraindications to exercise
- Uncontrolled hyperglycaemia
- BP >200/100 mmHg
- Febrile illness
- Unstable angina
- Acute heart failure
Patient Advice about Exercising

• Warm up before and cool down after exercise
• Wear proper footwear
• Monitor feet closely for blisters or any other damage to feet
• If exercising away from home, wear identification
• Ensure adequate intake of fluids
• Eat appropriately and modify insulin as necessary

PHARMACOLOGICAL MANAGEMENT OF HYPERGLYCAEMIA

Currently, the main therapeutic options for the treatment of Type 2 Diabetes are:

• Biguanides- Increase insulin sensitivity
• Thiazolidinediones- Increase insulin sensitivity
• Sulfonylureas- Increase insulin release
• Meglitinides- Increase insulin release
• Alpha-glucosidase inhibitors- Modify intestinal absorption of carbohydrates
• Insulins- Replace insulin

Combinations of these classes of drugs are frequently required for optimum control.

Low dose combination therapy could be considered early in the disease as it improves the efficacy of therapy and minimises side effects.

ORAL GLUCOSE-LOWERING AGENTS

Therapy with oral agents should be introduced when the blood sugar is not controlled by diet and exercise after 4-6 weeks.

The majority of persons with diabetes, even if initially controlled on non-pharmacological measures, will eventually require drug therapy in increasing
dosages and often in multiple drug regimens. Many subsequently require the addition or substitution of insulin for glycaemic control, the so-called secondary failure. A subset of patients with apparent Type 2 Diabetes Mellitus may require insulin for control somewhat earlier than expected—primary failure of response to oral therapy.
### Table 7:
Profile of Principal Oral Glucose-Lowering Agents

<table>
<thead>
<tr>
<th>Class</th>
<th>Action</th>
<th>Advantages</th>
<th>Contraindications</th>
<th>Side effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biguanides</td>
<td>Reduce hepatic glucose output and delay glucose absorption from the gut</td>
<td>Do not cause weight gain, low cost, effective</td>
<td>Renal insufficiency, hepatic insufficiency, severe heart failure</td>
<td>Lactic acidosis, gastrointestinal problems, hypoglycaemia</td>
</tr>
<tr>
<td>Metformin (This is the only drug used in this class)</td>
<td>Stimulate insulin release</td>
<td>Low cost, effective</td>
<td>Pregnancy, lactation</td>
<td>Gastrointestinal upset, hypoglycaemia, gastrointestinal symptoms</td>
</tr>
<tr>
<td>Sulphonylureas</td>
<td>Glipizide, Gliclazide, Glyburide, Glyoude (short acting)</td>
<td>Rapid-on-off effect due to short half life</td>
<td>Pregnancy, lactation</td>
<td>Gastrointestinal symptoms, hypoglycaemia</td>
</tr>
<tr>
<td>Meglitandines</td>
<td>Repaglinide</td>
<td>Do not cause hypoglycaemia</td>
<td>Pregnancy, kidney disease, cirrhosis</td>
<td>Gastrointestinal upset, hypoglycaemia</td>
</tr>
<tr>
<td>Alpha glucosidase inhibitors</td>
<td>Acarbose</td>
<td>Increase insulin sensitivity</td>
<td>Pregnancy, caused by pregnancy, kidney disease, cirrhosis</td>
<td>Gastrointestinal upset, hypoglycaemia</td>
</tr>
<tr>
<td>Thiazolidinediones</td>
<td>Rosiglitazone, Pioglitazone, e.g. Rosiglitazone, Pioglitazone</td>
<td>Increase insulin sensitivity</td>
<td>Cardiac failure, liver disease, caution when used with insulin</td>
<td>Water retention, weight gain</td>
</tr>
</tbody>
</table>

**Dosing**
- Start with 500 mg once or twice daily with meals
- Short acting drugs preferable for use in the elderly.
- Start with a low dose and increase as necessary.
- Multiple dosing regimen is necessary.
- Start with low dose 25 mg 2-3 times daily [take with the first bite of each main meal].
- Increase to maximally tolerated dose.
- Can be used as monotherapy or in combination with other oral agents or insulin.

**Note**
1) The current cost of thiazolidinediones and meglitandines prohibits their ready use in Primary Care. However, they can be used as first-line treatment in the elderly and should be avoided in those with renal disease.
2) Chlorpropamide, a long-acting sulphonylurea is not recommended. Where still available, it should be used with extreme caution in the elderly.
INSULIN

The indications for insulin treatment are:

- All Type 1 patients
- Patients with Type 2 diabetes, whose metabolic control is chronically inadequate evidenced by an HbA1c >6.5% despite adequate diet, weight reduction, exercise and maximum dosages of oral hypoglycaemic agents
- To cover acute illness, surgery or pregnancy (See Appendix IV)
- Treatment of diabetic ketoacidosis or hyperglycaemic/hyperosmolar non-ketotic diabetic states
- Post-myocardial infarction

Patients with Type 2 Diabetes who are failing or have failed oral therapy can be safely and effectively started on insulin in the outpatient setting, with proper advice and training by the health care team.

Table 8: Types of Insulin Available

<table>
<thead>
<tr>
<th>Type of Insulin</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rapid-acting</td>
<td>Insulin lispro</td>
</tr>
<tr>
<td></td>
<td>Insulin aspart</td>
</tr>
<tr>
<td>Short-acting</td>
<td>Regular</td>
</tr>
<tr>
<td></td>
<td>Humalog</td>
</tr>
<tr>
<td>Intermediate</td>
<td>NPH, Lente</td>
</tr>
<tr>
<td></td>
<td>Ultralente</td>
</tr>
<tr>
<td>Long-acting</td>
<td>Glargine</td>
</tr>
<tr>
<td></td>
<td>Detamir</td>
</tr>
<tr>
<td>Pre-mixed</td>
<td>70% Lente: 30% Regular</td>
</tr>
<tr>
<td></td>
<td>80% Lente: 20% Regular</td>
</tr>
</tbody>
</table>

Note: • Regular insulin should be injected subcutaneously 15-30 minutes before a meal for the onset of action to coincide with food absorption.
• Humalog (an analogue insulin) can be given at the start of the meal.
• Glargine is given once daily, preferably on mornings, either alone or in combination with short-acting insulin or oral agents.

Mixing of Insulins:
• If Lente or Ultralente is mixed with Regular insulin in a syringe, it should be injected immediately, or the action of the Regular insulin becomes impaired.
• Glargine should not be mixed in the syringe with other insulins or injected at the same site as other insulins.
• If it is necessary to mix short and long acting insulin, then NPH is preferable to Lente in mixing with Regular insulin.
• When insulins are mixed, the Regular insulin should be drawn up first before the Lente or Ultralente.

Possible Insulin Regimens In Type 2 Diabetes Mellitus

1] Combined oral agents and insulin:
• Morning: Oral agents e.g. Metformin or Sulphonylureas or Thiazolidinediones
• Bedtime: Glargine or NPH insulin: Start with 10 - 15 units and adjust to achieve target fasting values.

2] Twice Daily Regimen of Both ‘Regular’ and ‘NPH’ Insulin
• Use the ‘Rule of Thirds’
  • 1/3 short-acting insulin and 2/3 long-acting insulin
  • 2/3 of daily dose in morning and 1/3 in evening
Example
Assuming a total dose of 45 units of insulin is required per day for control

<table>
<thead>
<tr>
<th>Time</th>
<th>Regular</th>
<th>NPH</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.M:</td>
<td>2/3 of total daily dose (30 units)</td>
<td>10</td>
</tr>
<tr>
<td>P.M:</td>
<td>1/3 of total daily dose (15 units)</td>
<td>5</td>
</tr>
</tbody>
</table>

3) Multiple Dosing Regimen:
   Short-acting analogue e.g. Regular analogue immediately before each main meal together with long acting analogue insulin at bedtime e.g. Glargine

   This regimen is useful in patients with little control or those who desire flexibility due to their lifestyles. High levels of motivation, frequent testing and adjustment of dosages are necessary for good control on this regimen.

   Whenever possible, it may be useful to get input from a diabetes specialist.
MONITORING OF BLOOD GLUCOSE

SELF-MONITORING OF BLOOD GLUCOSE

Self-monitoring of blood glucose (SMBG) is a major component in the achievement of good glycaemic control. SMBG is particularly useful in persons with Type 1 diabetes but may also play a critical role in the management of persons with Type 2 Diabetes.

The main functions of SMBG are:

- To provide persons with diabetes with information about their response to therapy. This information can be used to make adjustments to diet, medication and physical activity.
- To foster the partnership between the patient and the health care team as results obtained by the patient may be used to modify treatment regimens.
- To detect hypoglycaemia especially in those who may be ill or unaware of relevant symptoms.
- To allow persons with diabetes to be aware of the status of their blood glucose control without being solely dependent on health care professionals.
- To empower persons with diabetes.

An individualized home monitoring plan is required and must be agreeable to the patient and health care workers. The plan should include the timing and frequency of tests. Frequency will vary according to the type of diabetes, the medication prescribed and the level of glycaemic control.

Testing should be done in the fasted state as well as before and after meals. For persons with Type 1 Diabetes and pregnant women on insulin, SMBG should be done at least three times per day. Recorded results should be presented to
health care professionals at clinic visits. The person’s ability to adjust treatment, food and physical activity according to the results should also be monitored.

SMBG may not be suitable for everyone with diabetes. The patient should be able to perform the test accurately, following the manufacturer's instructions, and must know what results to expect and what action to take if the results are outside the desired range.

Major limitations of SMBG are:
• the cost of the testing strips and
• difficulties experienced by some persons in pricking themselves (needle phobia).

**BLOOD GLUCOSE MONITORS**

There is usually a reasonable correlation between glucose concentrations measured in capillary blood by glucose meters and those from serum or plasma glucose measured by clinical laboratory procedures.

**BLOOD GLUCOSE TESTING**

The technique of testing should be taught by members of the health care team who should ensure that the test is being done accurately.

It is important to ensure that strips match the machine.

Strips must be stored according to recommendations of the manufacturers.

**HbA1c**

This test is used in combination with self-monitoring of blood glucose to assess long-term control.

Testing should be done as a minimum once every 6 months.
URINE TESTING

- Urine testing for glucose is **not recommended for evaluating control**. In settings where this may be the only available option for monitoring glycaemic control, persistent glycosuria highlights the need for the patient to seek further medical attention.

- Urine testing for ketones is important during sick days especially for Type 1 diabetes. [See Appendix IV]

HYPOGLYCAEMIA

Hypoglycaemia/Hypo is used to describe blood sugar levels **below 4 mmol/L**.

**Possible causes:**
- More exercise than normal
- Too little food
- Missed or late meals
- Too much insulin/tablets
- Alcohol consumption
- Menses
- Hot weather

**Signs and symptoms** include:
- Sweating
- Shaking
- Dizziness
- Tiredness
- Hunger
- Blurred vision
- Headaches
- Tingling lips/finger tips

May also notice:
- Glazed eyes
- Mood changes
- Unusually aggressive behaviour
THE THREE STAGES OF HYPOGLYCAEMIA

1. **Mild Hypoglycaemia**

Characterized by shaking, sweating, hunger, weakness and anxiousness

**Treatment**
Self-treatment of 10 to 15 grams of pure glucose, wait 10 minutes and follow with a protein such as 8 oz. of milk or cheese and crackers or bread. If untreated, it progresses to moderate hypoglycemia.

2. **Moderate Hypoglycaemia**

Characterized by confusion, slurred speech, glassy eyes, poor coordination and lack of concentration

**Treatment**
Assistance may be required. Take a 20 to 30 gram dose of pure glucose, wait 10 minutes then follow with a protein such as 8 oz. milk or cheese and crackers or bread. If untreated, it progresses to severe hypoglycaemia.

3. **Severe Hypoglycaemia**

Characterized by unresponsiveness, combativeness, agitation, convulsions and unconsciousness

**Treatment:**
This is an acute medical emergency. Seek medical assistance.

Severe hypoglycaemia can be life threatening if not treated promptly and thoroughly. Emergency measures are required, including injection of glucagon or intravenous dextrose, followed by oral glucose or sweetened drinks.

Hospital admission is indicated for severe or prolonged hypoglycaemia, co-existing renal disease or illness associated with use of long acting oral glucose lowering agents. The usual dose of insulin/diabetic medication may need to be modified, once the hypo episode has been treated.

Encourage patients to carry glucose and snacks at all times.
CONDITIONS IN DIABETES MELLITUS REQUIRING HOSPITAL ADMISSION

- Newly diagnosed diabetes in children and adolescents or in pregnancy
- Uncontrolled diabetes
  - Chronic refractory hyperglycaemia associated with metabolic deterioration
  - Inability to obtain glycaemic control with outpatient therapy
  - Recurrent hypoglycaemia
  - Metabolic instability characterized by frequent swings between hypoglycaemia and hyperglycaemia
  - Recurrent diabetic ketoacidosis in the absence of trauma and infection
  - Uncontrolled diabetes in pregnancy
- Institution of intensive insulin regimes including insulin-pump therapy
- Potentially life-threatening acute complications of diabetes
  - Diabetic ketoacidosis characterized by hyperglycemia, acidosis and ketones in the urine and/or blood
  - Hyperglycemic hyperosmolar state characterized by severe hyperglycemia and elevated serum osmolality often with concomitant alterations in mental status
  - Hypoglycemia with neuroglycopenia characterized by altered consciousness, seizures, coma, or disturbances of motor or language function, where there has not been prompt full recovery following glucose therapy, a sulfonylurea drug has been implicated, or there is concern about patient supervision or monitoring.
MANAGEMENT OF ASSOCIATED CONDITIONS

Because of the interrelationship of diabetes with co-morbidities, there is a need for those conditions to also be controlled to prevent or delay complications and improve quality of life.

HYPERTENSION MANAGEMENT IN ADULTS WITH DIABETES

There is a higher prevalence of hypertension among persons with diabetes compared with non-diabetics. In the Caribbean diabetes is present in about one-third of hypertensive patients. This co-existence is often a result of:

- The high prevalence of both conditions in the Region
- The relationship between insulin resistance and hypertension
- The higher prevalence of chronic renal disease among diabetic patients

Hypertension increases the risk of strokes, ischaemic heart disease, retinopathy and nephropathy in persons with diabetes.

The target blood pressure should be <130/80 mm Hg. However, attaining systolic pressures of <120 mm Hg is desirable.

Such targets may be difficult to achieve in the elderly and more modest goals may have to be set.

Management

Non-drug Treatment

- Weight management must be recommended for all persons with diabetes. Caloric restriction and any degree of weight loss are beneficial for the overweight or obese patient.

The intake of potassium and calcium must be adequate and sodium intake limited. Increased consumption of fruits and vegetables is to be encouraged as well as the use of low fat dairy products. A balanced diet will provide all the essential nutrients and vitamins without the need for supplementation.

See “Protocol on the Nutritional Management of Obesity, Diabetes and Hypertension in the Caribbean” for further details.
• Smoking cessation is critical for reducing the risk of vascular complications of hypertension and diabetes.

• Alcohol intake should be limited as it compromises the control of both diabetes and hypertension.

• Physical activity should be continued unless specifically contraindicated.

**Drug Treatment**

• Most persons with hypertension and diabetes will need 2 or more drugs for control, in addition to lifestyle changes.

• Low-dose Thiazides e.g. Bendrofluazide or Hydrochlorothiazide can be used safely in the majority of diabetics. Thiazides, used in low doses, rarely affect glucose, lipids or electrolyte balance and should be the antihypertensives of first choice.

• Diuretics, ACE inhibitors, Angiotensin Receptor Blockers (ARBs) and Calcium Channel Blockers (CCBs) have all been shown to reduce the risk of cardiovascular events.

• ACE inhibitors have been shown to improve cardiovascular outcomes in high-risk patients with or without hypertension and there is compelling evidence for earlier use in persons with diabetes.

• ACE inhibitors or ARBs are the drugs of choice for renal protection in diabetics with proteinuria. In persons who are allergic to ACE/ARBs, the use of the calcium channel blocker Diltiazem has provided similar benefits.

• Beta-blockers have a place in the management of persons with diabetes but should be used with caution in persons with peripheral vascular disease. Water soluble forms e.g. Atenolol are preferable.

See **"Managing Hypertension in Primary Care in the Caribbean"** for further details.
LIPID MANAGEMENT IN ADULTS WITH DIABETES

Type 2 Diabetes mellitus is associated with increased prevalence of lipid abnormalities (viz. increased low density lipoproteins (↑LDL-C), decreased high density lipoproteins (↓HDL-C) and increased triglycerides (↑TG), which contribute to macrovascular disease (heart attacks and strokes).

Lowering LDL cholesterol and triglycerides and raising HDL cholesterol have been shown to reduce macrovascular disease events as well as mortality.

General Points

- Diet and exercise remain the cornerstone of treatment of dyslipidaemia.
- Pharmacological therapy is often required to achieve targets and should be implemented in conjunction with lifestyle changes.
- Routine screening of all diabetes patients for dyslipidaemia is to be encouraged through annual testing.

Treatment

**LDL-cholesterol**

- Aim for LDL-cholesterol <70 mg/dL (<1.8 mmol/L). Statins are the drug of choice.

**HDL-cholesterol**

- Aim for >40 mg/dL (>1.0 mmol/L)
- Nicotinic acid (Niacin) is the most effective drug for raising HDL-C but has limited usage in clinical practice, as a result of an unpleasant flushing reaction. When used, doses should be restricted (e.g. 500–1000 mg per day) to reduce the likelihood of hyperglycaemia.
Hypertriglyceridaemia

- Aim for <150mg/dL (<1.7 mmol/L)
- This derangement frequently responds to calorie and alcohol restriction. Adequate glycaemic control also contributes to reductions in triglyceride levels.
- Fibrate therapy [e.g. Gemfibrozil] may be necessary if these measures fail.

Statin therapy

- Patients with diabetes who have other cardiovascular risk factors (such as hypertension, smoking or microalbuminuria), may benefit from the addition of a statin irrespective of initial LDL-cholesterol levels.
- All diabetic patients with cardiovascular disease [angina, myocardial infarction, transient ischaemic attack, stroke, and claudication] should be on cholesterol-lowering medication.
- Combination therapy with a statin and fibrates may be used for mixed lipid disorders but the risk of rhabdomyolysis is increased.
- Note that liver function should be evaluated before commencement of statin therapy

OTHER THERAPEUTIC INTERVENTIONS

The following therapies may be considered in the management of diabetes and associated conditions.

- Anti-thrombotics
  Aspirin (75-325 mg daily) should be given to all persons with diabetes over age 40 years who do not have a contra-indication to aspirin therapy and who have two or more risk factors for cardiovascular disease.

  **Note:** Higher doses will increase the possibility of gastric mucosal injury and gastrointestinal haemorrhage.
Aspirin is not recommended for persons under age 21 years because of increased risk of Reye’s Syndrome

Alternative therapies include the combination of aspirin with an H2 antagonist or proton pump inhibitors or the use of Clopidogrel.

- **Anti-obesity drugs**
  These drugs should only be used when absolutely necessary. Current choices include Orlistat and Sibutramine
Section IV: Prevention and Reduction of Complications
The microvascular complications of diabetes mellitus i.e. nephropathy, neuropathy and retinopathy are directly related to the duration and degree of glycaemic control.

**Nephropathy**

This is a major cause of end-stage renal disease (ESRD)

**Contributing Factors**

- Duration of diabetes (usually >10 years)
- Poor glycaemic control
- Poor blood pressure control
- Genetics- family history of hypertension or renal failure
- High protein intake

**Screening for Nephropathy**

Albuminuria is the earliest manifestation of nephropathy

Main methods for screening

- Measurement of urinary albumin/creatinine ratio (ACR)
- 24 hour collection of urine for proteinuria
- Timed collection of urine for microalbumin
Table 9:
Definition of Abnormalities in Renal Albumin Excretion

<table>
<thead>
<tr>
<th>Category</th>
<th>Spot collection µg/mg creatinine</th>
<th>24-hr collection mg/24 h</th>
<th>Timed collection µg/min</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>&lt;30</td>
<td>&lt;30</td>
<td>&lt;20</td>
</tr>
<tr>
<td>Microalbuminuria</td>
<td>30-299</td>
<td>30-299</td>
<td>20-199</td>
</tr>
<tr>
<td>Clinical albuminuria</td>
<td>≥300</td>
<td>≥300</td>
<td>≥200</td>
</tr>
</tbody>
</table>

Source: American Diabetes Association, Clinical Guidelines of Care, 2005

RECOMMENDATIONS TO REDUCE THE RISK OF NEPHROPATHY

- Screen for microalbuminuria at diagnosis and then annually in all persons with Type 2 diabetes mellitus.

Once microalbuminuria or proteinuria has been confirmed:

- Include an ACE-inhibitor or ARB in the therapeutic regimen.
- Aim for tight blood pressure control with combination therapy if necessary so that BP ≤ 125/75 mmHg.
- Aim for tight glycaemic control.
- Advise on a protein restricted diet and refer to a nutritionist/dietitian for specialized management.
- Refer for specialist care.
RETINOPATHY

Diabetic retinopathy is an important cause of blindness.

**Contributing Factors**
- Duration of the disease (usually >10 years)
- Poor glycaemic control
- Poor blood pressure control

**Screening**
Refer all persons with Type 2 diabetes mellitus to an ophthalmologist as soon as possible after initial diagnosis and then annually for dilated fundoscopy. Patients with Type 1 diabetes should have an initial eye examination 3-5 years after the onset of the disease.

**Recommendations to Reduce Risk of Retinopathy**
- Aim for tight metabolic and blood pressure control
- Refer for specialty care

NEUROPATHY

Diabetic neuropathy occurs mainly in persons with poor glycaemic control. The symptoms are:
- Tingling
- Numbness
- Weakness
- Burning sensations

Symptoms usually start at the periphery (fingers and toes) and move up the limbs.

If the autonomic nervous system is affected, abnormalities of bladder and bowel function and penile erectile dysfunction (ED) may also occur.
CARE OF THE FOOT

Foot lesions are common in persons with diabetes. See Appendix V.

Factors that Contribute to Foot Lesions
- Neuropathy
- Ischaemia
- Injury/Infection
- Incorrect foot wear

Recommendations to Reduce the Risk of Foot Problems
- Aim for tight metabolic and blood pressure control
- Encourage smoking cessation
- Encourage routine daily self-examination of feet
- Encourage use of correct foot wear. Where available, a chiropodist or podiatrist should be consulted when necessary
- Examine peripheral pulses for peripheral vascular disease
- Test feet routinely for peripheral neuropathy
- Refer for specialty care as appropriate

CARDIOVASCULAR DISEASE

Persons with diabetes are at significantly increased risk of developing cardiovascular disease, which is the major cause of mortality and chronic morbidity.

Cardiovascular disease includes:
- Coronary heart disease, which can lead to angina and myocardial infarction
- Cerebrovascular disease leading to transient ischaemic attacks and strokes
- Peripheral vascular disease
In terms of risk stratification, persons with diabetes should be treated in an identical manner to persons without diabetes who have previously had a heart attack.

In addition to glycaemic and blood pressure control and correction of dyslipidaemias, the following are strongly advised:

- **Smoking Cessation**
  - Successful smoking cessation is the most effective intervention for both primary and secondary prevention of cardiovascular disease.

- **Use of Anti-Platelet Agents**
  - Primary prevention with an anti-platelet agent should be considered in all patients over the age of 40 years, especially those with multiple risk factors.
  - Aspirin use is beneficial for secondary prevention following myocardial infarction, stroke, peripheral vascular disease, angina or following surgery for any of these conditions.
Section V: Management of Gestational Diabetes Mellitus
GESTATIONAL DIABETES MELLITUS (GDM)

Gestational diabetes mellitus is defined as any degree of glucose intolerance with onset or first recognition during pregnancy.\(^2\)

The following categories of patients are at increased risk of GDM:
- > 25 years of age
- overweight
- first degree family history of diabetes
- previous history of abnormal glucose metabolism
- glycosuria
- previous poor obstetric history
- ethnicity associated with high prevalence of diabetes mellitus
- a previous large baby weighing more than 4.0 kg (9lbs)

Gestational diabetes poses a high-risk for both the woman and the child.

Complications of GDM include:

**Fetus/Child**
- Congenital malformations
- Increased birth weight
- Shoulder dystocia
- Elevated risk of perinatal mortality

\(^2\) American Diabetes Association 2005 Guidelines of Care
Mother
- Hypertension in pregnancy and placental insufficiency may occur more frequently
- Increased insulin resistance
- Development of diabetes-related complications
- Abortion

PROTOCOL FOR TESTING FOR GESTATIONAL DIABETES MELLITUS

1) Screen with questions related to risk factors as above
2) High-risk patients should be tested with the Oral Glucose Tolerance Test

If the first test is normal, retest high-risk patients at 24-28 weeks gestation.

DIAGNOSTIC CRITERIA

There are two main glucose tolerance tests used for diagnosing gestational diabetes.

The test using 100 g glucose is also widely used for detection of ‘at risk’ infants and mothers.
Table 10:
Glucose Tolerance Tests for Gestational Diabetes

100g glucose (Traditional Method)

<table>
<thead>
<tr>
<th>Time</th>
<th>mg/dL</th>
<th>mmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting</td>
<td>&gt; 95</td>
<td>&gt; 5.3</td>
</tr>
<tr>
<td>1-h</td>
<td>&gt;180</td>
<td>&gt; 10.0</td>
</tr>
<tr>
<td>2-h</td>
<td>&gt;155</td>
<td>&gt; 8.6</td>
</tr>
<tr>
<td>3-h</td>
<td>&gt;140</td>
<td>&gt;7.8</td>
</tr>
</tbody>
</table>

75 g glucose

<table>
<thead>
<tr>
<th>Time</th>
<th>mg/dL</th>
<th>mmol/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting</td>
<td>&gt; 95</td>
<td>&gt; 5.3</td>
</tr>
<tr>
<td>1-h</td>
<td>&gt;180</td>
<td>&gt; 10.0</td>
</tr>
<tr>
<td>2-h</td>
<td>&gt;155</td>
<td>&gt; 8.6</td>
</tr>
</tbody>
</table>

**Note:** Clinical practice includes the use of a screening 50g glucose load (fasting not required). If the one hour value is ≥140 mg/dL (≥ 7.8 mmol/L), proceed to a diagnostic OGGT.

The alternative is the single step approach using the diagnostic GTT.

**Two or more of venous plasma concentrations must be met or exceeded for a positive diagnosis.**

**REFERRAL**

All cases of GDM should be referred to a specialist centre for care and delivery.
POST-PARTUM FOLLOW UP

Although most women with gestational diabetes mellitus revert to normal glucose levels after pregnancy, they are at significant risk of developing GDM in subsequent pregnancies as well as Type 2 Diabetes later in life. Intense lifestyle modification should be encouraged with annual routine screening for diabetes starting at the 6 week post-partum visit.
Section VI:

Effective Self Care Through Education
SELF-MANAGEMENT EDUCATION GOALS

The following goals are a guide for the entire health care team which should work together to achieve them.

Always remember that the main member of the team is the PERSON LIVING WITH DIABETES and that he/she should be totally involved in goal and priority setting

• Describing the disease process and treatment options
  o Identify diabetes as a disorder in which the body is unable to utilise food properly
  o Describe the actions of insulin and what happens in the body when insulin is not available or does not work properly
  o Explain how the prescribed meal and exercise plan and blood glucose monitoring are essential for management of the disease
  o List the risk factors for diabetes
  o State how the diagnosis of diabetes is established
  o State the importance and benefits of good diabetes control
  o Describe the effects of oral hypoglycaemic agents

• Incorporating appropriate nutritional management
  o State that nutrition therapy and meal planning are essential components in the control of blood glucose
  o List the goals:
    • Identifying appropriate body weight (explain BMI)
    • Importance of reaching and maintaining appropriate body weight
• Controlling blood glucose and lipids
• Practising good nutrition
  o Discuss types of nutrients that affect blood glucose and lipid levels
  o List the types and amounts of foods to include in meals as indicated in the meal plan
  o State the relationship of food and meals to blood glucose levels, medication and activity
  o Discuss meal-planning strategies to meet the goals
  o Demonstrate the correct portion sizes for the meal plan
  o Identify times for snacks
  o Demonstrate how to evaluate food products using food labels
  o Discuss use of non-caloric sweeteners
  o Explain importance of reducing total fat as well as saturated and hydrogenated fats
  o State the relationship of salt and hypertension
    • Discuss ways to reduce salt
  o State the effect of alcohol on blood glucose
  o Describe how to prevent and manage hypoglycaemic attacks
  o State the relationship between obesity and diabetes and the benefits of weight loss

• Incorporating physical activity into lifestyle
  o State that exercise is recommended for diabetes management and good health in general
  o State that exercise can help lower blood glucose levels
  o Describe role of physical activity on a regular basis to achieve or maintain appropriate body weight
  o State the need to consult with the health care team before beginning an exercise program
  o List types of physical activity that the patient agrees to use
o Describe the proper shoes and clothing to use
o State why and how to avoid dehydration
o State that hypoglycaemia can result from exercise if certain medications are used
  • State relationship of exercise to oral agent activity
    - Timing of meals and exercise
  • List factors that may increase the risk of exercise-induced hypoglycaemia
    - Alcohol and β-blockers

• Using medications for therapeutic effectiveness
  o State that in addition to diet and exercise some individuals may need either oral agents or insulin
  o State that the oral medication dosage is individualised
  o State the action of oral medication on blood glucose level
  o State the name of oral medication, its dosage and when it is to be taken
  o List the possible side effects of oral medication
  o State the possible interactions of diabetes medications with other medications taken

• Monitoring
  o Describe rationale for monitoring blood glucose
  o Demonstrate how to perform tests with appropriate materials
  o Demonstrate how to record results
  o Demonstrate proper disposal of lancets and other materials
  o State when and how to contact health care provider if results are consistently higher or lower than guidelines given
• Preventing, detecting and treating chronic complications
  o Identify chronic complications associated with diabetes
  o State that near-normal blood glucose may prevent or delay chronic complications
  o State that smoking increases risk of complications
  o State the need for an eye examination on a regular basis
  o State that diabetes can affect the eyes without any symptoms being initially apparent
  o State the need for daily foot inspection and for wearing well fitting shoes
  o Demonstrate how to bathe feet and trim toenails safely
  o Identify factors that may cause injury to the feet
  o State the need to report early symptoms of potentially serious problems
  o State the need for daily dental and mouth care
  o Identify the organ systems particularly at risk from diabetes
  o State that regular blood pressure monitoring is necessary
    • Need to control high blood pressure
  o State that monitoring of cholesterol and triglycerides is necessary
    • State differences between HDL-C and LDL-C
  o State that diabetes may cause sexual dysfunction and identify resources for help
REFERENCES


Caribbean Health Research Council. Managing Hypertension in Primary Care in the Caribbean. CHRC; St. Augustine, Trinidad and Tobago, 2006.


Kissebah AH. Central obesity: measurement and metabolic effects. *Diabetes Rev*. 1997;5:8-20


### ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE Inhibitor</td>
<td>Angiotensin-converting Enzyme Inhibitor</td>
</tr>
<tr>
<td>BMI</td>
<td>Body Mass Index</td>
</tr>
<tr>
<td>FPG</td>
<td>Fasting Plasma Glucose</td>
</tr>
<tr>
<td>GDM</td>
<td>Gestational Diabetes Mellitus</td>
</tr>
<tr>
<td>HbA1c</td>
<td>Glycated (or glycosylated) Haemoglobin</td>
</tr>
<tr>
<td>HDL-C</td>
<td>High Density Lipoprotein cholesterol</td>
</tr>
<tr>
<td>IFG</td>
<td>Impaired Fasting Glucose</td>
</tr>
<tr>
<td>IGT</td>
<td>Impaired Glucose Tolerance</td>
</tr>
<tr>
<td>LDL-C</td>
<td>Low Density Lipoprotein cholesterol</td>
</tr>
<tr>
<td>NPH</td>
<td>Neutral Protamine Hagedorn</td>
</tr>
<tr>
<td>OGTT</td>
<td>Oral Glucose Tolerance Test</td>
</tr>
<tr>
<td>SMBG</td>
<td>Self Monitoring of Blood Glucose</td>
</tr>
<tr>
<td>TG</td>
<td>Triglycerides</td>
</tr>
<tr>
<td>UKPDS</td>
<td>UK Prospective Diabetes Study</td>
</tr>
<tr>
<td>VLDL cholesterol</td>
<td>Very Low Density Lipoprotein cholesterol</td>
</tr>
</tbody>
</table>
Appendices

Appendix I: Body Mass Index (BMI) Chart for Identifying Target Weight

Produced by the Caribbean Food & Nutrition Institute - A Specialized Centre of the Pan American Health Organization/World Health Organization - 2002
Body Mass Index classification

<table>
<thead>
<tr>
<th>BMI</th>
<th>Weight/height $^2$ (kg/m$^2$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>18.5 - 24.9</td>
</tr>
<tr>
<td>Overweight</td>
<td>25 - 29.9</td>
</tr>
<tr>
<td>Obese</td>
<td>30 - 39.9</td>
</tr>
<tr>
<td>Morbidly obese</td>
<td>40+</td>
</tr>
</tbody>
</table>

How to use the BMI Charts

1. Take the weight of the client (ensure that this is accurately taken) and record it.
2. Take the height of the client (ensure that this is accurately taken) and record it.
3. On the BMI chart use the top or bottom column headings (top heading shows weight in pounds and bottom shows weight in kilos) to find the weight measured.
4. On the BMI chart use the left or right row headings (left margin shows height in feet and inches and right shows height in meters) to find the height measured.
5. Using the weight and the height identified, see where the weight column and height row meet. This will give you the Body Mass Index (BMI) of the person measured.
6. Using the guide at the bottom of the BMI Chart, check the colour of the square to identify the classification of the client.

Example 1:

1. Person’s weight is 190 lbs (86 kg)
2. Person’s height is 5ft 9 inches (1.75 m)
3. The number in the box where the weight column and height row intersect is 28.
4. BMI is 28 and colour of box is yellow, which is classified as Overweight.
Appendix II: Recommended Composition of Healthy Diets

A healthy diet?

If all the foods you eat each day were arranged on one large plate, the amounts should look like this:

- **Fruits & Vegetables**: About 1/2 of the day’s food should be chosen from this group.
- **Ground Provisions**: Eat regularly.
- **Cereals**: Eat regularly.
- **Legumes & Nuts**: Eat regularly.
- **Fats & Oils**: Use very little and always choose low fat products.

**Foods from Animals & Alternatives**: Limit usage and choose low fat.

Developed by: Dan Ramdath with the Assistance of Debra Ramdath and Troy Jennings
Appendix III: Diabetes Management Flow Sheet

Name ...........................................................................................................................................................................

Date of Birth ...................................................................................................................................................................

Height ...............................................................................................................................................................................

Target body weight........................................................................................................................................................

Sex   M   F

CHECK EVERY VISIT

<table>
<thead>
<tr>
<th>Date</th>
<th>Weight/BMI</th>
<th>Home monitoring results</th>
<th>Blood glucose</th>
<th>Blood pressure</th>
<th>Dietary advice</th>
<th>Exercise advice</th>
<th>Foot inspection</th>
<th>Smoking/alcohol</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Drug 1

Drug 2

Drug 3

Drug 4

Drug 5

Adherence with treatment

State of injection sites for insulin treatment
### CHECK AT LEAST ONCE EVERY YEAR

<table>
<thead>
<tr>
<th>Date</th>
<th>Foot pulses</th>
<th>Foot sensation</th>
<th>Visual acuity</th>
<th>Fundoscopy</th>
<th>Urine protein</th>
<th>Blood urea/creatinine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Cholesterol**
- HDL-C
- LDL-C
- Triglycerides

**HbA1c** (preferably every 3-6 months)

<table>
<thead>
<tr>
<th>Waist circumference</th>
<th>Oral Health</th>
<th>Mental Health</th>
<th>ECG</th>
<th>Smoking</th>
<th>Alcohol</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Appendix IV: Sick Day Rules

When a person on insulin has a cold, the flu, a stomach upset, sore throat, urinary tract infection, chest infection or other illnesses of short duration, the blood glucose might increase. The following rules should be followed to ensure that blood glucose levels remain well controlled.

- **Continue SMBG**
  Illness or infection can result in an increase in the amount of insulin that the body needs and cause an increase in blood glucose. Home monitoring of blood glucose is recommended.

- **Test urine for Ketones**
  This is also important to ensure that the blood glucose and insulin levels are appropriate.

- **Continue with Insulin**
  Clients should be told never to stop taking insulin. They may require less insulin if their appetite is poor but as illness usually increases the body’s demand for insulin the regular dose should not be stopped.

- **Review dietary needs**
  Since illness is often accompanied by decreased appetite, the diet and meal plan may need to be revisited and substitute foods used which are more easily digested. More frequent, smaller meals may be better tolerated. The exchange lists should be used to determine appropriate food substitutes.

- **Maintain contact with the health care team**
  Clients should be made aware that they should contact the health care team if:
  - They are vomiting
  - They have ketones in their urine
  - Their blood sugar is consistently higher than usual
  - They are unable to eat and/or drink
  - They have a fever
  - They have diarrhoea and/or nausea persisting for more than 24 hours
  - They have abdominal pain
  - They are not sure what to do!

**NOTE:**
Those clients who are taking oral hypoglycaemic agents should also communicate with the health care team if they have fever, diarrhoea, infection or vomiting as the oral agent they are using may not be appropriate in dose or type.
Appendix V: Care of the Foot in Persons with Diabetes

Patients should be advised to:
- Perform daily examination of feet using mirrors to observe sole of feet or with the assistance of a relative
- Never walk barefooted indoors or outdoors
- Never cut corns, bunions nor use corn pads
- Avoid corn cures, paints or plasters
- Seek assistance with cutting of nails
- Wear comfortable, loose fitting shoes
- Avoid open sandals. Use sandals with good protection of the feet.
- Keep feet clean and dry
- Cover any minor cuts
- Never use iodine on the foot
- Never prick blisters

Comfortable Shoes
Diabetics often cannot tell if a shoe is uncomfortable because feet may be insensitive due to neuropathy. Therefore, advise as follows:
- Ensure that they have enough time to purchase shoes. Purchase shoes in the afternoon
- Look at shoe and compare to shape of their feet. They should be similar
- There should be a deep toe box to allow the toes to function and correct width to accommodate the widest part of the foot. Shoe size should allow 1 inch of space between tips of toes and front of shoe.
- Shoe should have an effective fastening e.g. lace, strap or velcro.
- Leather uppers are preferable.
- The seamless styled shoe uppers are better; and a thick, soft and comfortable cushioning sole that aids with shock absorption and reduces the probability of being punctured through the shoe.
- Spend a few minutes walking in the shoes to ensure that they are comfortable

Consult doctor/podiatrist/chiropodist if there is:
- Colour change in any part of the foot or leg
- Discharge coming from break in skin
- Any pain, throbbing, swelling or itching
## Members of the Guidelines Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Position/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Michael Boyne</td>
<td>Lecturer in Endocrinology, Tropical Research Metabolism Unit University of the West Indies (UWI)</td>
</tr>
<tr>
<td>Dr Anne Carter</td>
<td>Senior Lecturer, Chronic Disease Research Centre, School of Clinical Medicine and Research, University of the West Indies, Barbados</td>
</tr>
<tr>
<td>Dr Ramsunder Doobay</td>
<td>Principal Physician, Georgetown Public Hospital, Guyana</td>
</tr>
<tr>
<td>Dr Livingstone Forde</td>
<td>Lecturer, School of Clinical Medicine and Research, University of the West Indies, Barbados</td>
</tr>
<tr>
<td>Professor Henry Fraser</td>
<td>Dean, School of Clinical Medicine and Research, University of the West Indies, Barbados</td>
</tr>
<tr>
<td>Dr Carlisle Goddard</td>
<td>Clinical Medical Officer, Ministry of Health, Barbados</td>
</tr>
<tr>
<td>Dr Anselm Hennis</td>
<td>Senior Lecturer, Chronic Disease Research Centre, Tropical Medicine Research Institute, University of the West Indies, Barbados</td>
</tr>
<tr>
<td>Dr Oscar Jordan</td>
<td>Director, Diabetes Foundation of Barbados</td>
</tr>
<tr>
<td>Dr Glenda Maynard</td>
<td>Chronic Disease/Mental Health Advisor, Office of Caribbean Program Coordination, Pan American Health Organization</td>
</tr>
<tr>
<td>Dr Vishal Poddar</td>
<td>Lecturer in Medicine, School of Clinical Medicine and Research, University of the West Indies, Barbados</td>
</tr>
<tr>
<td>Dr Pauline Samuda</td>
<td>Nutrition Educator, Caribbean Food and Nutrition Institute, Jamaica</td>
</tr>
<tr>
<td>Dr Donald Simeon</td>
<td>Director, Caribbean Health Research Council, Trinidad and Tobago</td>
</tr>
<tr>
<td>Prof Rainford Wilks</td>
<td>Professor, Epidemiology Research Unit, Tropical Medicine Research Institute, UWI, Jamaica</td>
</tr>
<tr>
<td>Mr Godfrey Xuereb</td>
<td>Public Health Nutritionist, Caribbean Food and Nutrition Institute, Jamaica</td>
</tr>
</tbody>
</table>